Seelos Therapeutics

Seelos Therapeutics receives grant money from research foundation to treat Sanfillipo Syndrome

Team San Sanfilippo Foundation representatives told Proactive Investors the nonprofit medical research foundation has contributed grant money towards New York-based biotech Seelos Therapeutics Inc's (NASDAQ:SEEL) upcoming clinical study to treat Sanfillipo Syndrome.

Team San Filippo Foundation Treasurer Danielle O'Connor, along with President Kathleen Buckley and Vice President Patricia Taormino say the nonprofit will fund Seelos which will begin initial patient dosing with its SLS-005 therapy in the third quarter of 2019.

Quick facts: Seelos Therapeutics

Price: $1.65

Market: NASDAQ
Market Cap: $37.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...



PFS values Infinity Lithium's flagship San José project at US$860mln

Infinity Lithium Corporation Ltd's (ASX:INF) executive director of corporate strategy Vincent Ledoux Pedailles chats to Proactive London's Andrew Scott following the publication of a PFS (pre-feasibility study) for the development of its flagship San José lithium project in Spain. The study...

25 minutes ago

2 min read